MARKET

SAVA

SAVA

Cassava Sciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.79
+1.55
+8.06%
Opening 14:56 05/16 EDT
OPEN
18.86
PREV CLOSE
19.24
HIGH
22.47
LOW
18.81
VOLUME
1.32M
TURNOVER
18.33M
52 WEEK HIGH
146.16
52 WEEK LOW
15.72
MARKET CAP
833.28M
P/E (TTM)
-17.9101
1D
5D
1M
3M
1Y
5Y
How Is The Market Feeling About Cassava Sciences?
Cassava Sciences's (NASDAQ:SAVA) short percent of float has risen 7.39% since its last report. The company recently reported that it has 11.46 million shares sold short, which is 31.54% of all regular shares that are available for trading.
Benzinga · 4d ago
Cassava can fully enroll late-stage Alzheimer’s studies by early 2023 - H.C. Wainwright
Commenting on the update provided by Cassava Sciences (NASDAQ:SAVA) on its Phase 3 program for Alzheimer’s candidate simufilam on Thursday, H.C. Wainwright says that the clinical-stage biotech is on track
Seekingalpha · 05/06 12:35
--B. Riley Lowers Cassava Sciences' Price Target to $58 from $72 to Factor in Increased Pace of Research & Development Expenses; Keeps Buy Rating
MT Newswires · 05/06 10:18
Recap: Cassava Sciences Q1 Earnings
  Cassava Sciences (NASDAQ:SAVA) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 14:53
Cassava Sciences issues enrollment update on late-stage Alzheimer’s studies
With its 1Q 2022 results, Alzheimer’s drug developer, Cassava Sciences (NASDAQ:SAVA), said on Thursday that the company’s late-stage program for the experimental therapy Simufilam has so far enrolled more than
Seekingalpha · 05/05 14:05
Cassava Sciences GAAP EPS of -$0.44 misses by $0.01
Cassava Sciences press release (NASDAQ:SAVA): Q1 GAAP EPS of -$0.44 misses by $0.01. At March 31, 2022, cash and cash equivalents were $209.7 million, with no debt. A total of
Seekingalpha · 05/05 13:17
BRIEF-Cassava Sciences Q1 Loss Per Share $0.44
reuters.com · 05/05 13:14
What Are Whales Doing With Cassava Sciences
Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Benzinga · 05/04 18:06
More
No Data
Learn about the latest financial forecast of SAVA. Analyze the recent business situations of Cassava Sciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
75.00%Buy
0.00%Hold
25.00%Under-perform
0.00%Sell
Analyst Price Target
The average SAVA stock price target is 92.50 with a high estimate of 180.00 and a low estimate of 8.00.
High180.00
Average92.50
Low8.00
Current 20.82
EPS
Actual
Estimate
-0.35-0.26-0.18-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 187
Institutional Holdings: 13.48M
% Owned: 33.62%
Shares Outstanding: 40.08M
TypeInstitutionsShares
Increased
57
867.48K
New
31
889.34K
Decreased
52
1.31M
Sold Out
39
781.58K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Chairman/Director/President/Chief Executive Officer
Remi Barbier
Chief Financial Officer
Eric Schoen
Other/Director
Nadav Friedmann
Other
James Kupiec
Lead Director/Independent Director
Sanford Robertson
Independent Director
Richard Barry
Independent Director
Robert Gussin
Independent Director
Michael O'Donnell
Independent Director
Patrick Scannon
No Data
No Data
About SAVA
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimers disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.

Webull offers kinds of Cassava Sciences Inc stock information, including NASDAQ:SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.